Through the partnership, Bethyl's research antibodies will be accelerated into the clinical market. Biocare will provide Bethyl with premier access to its Valent automated immunohistochemistry platform to develop products for early-stage research, companion diagnostics development, and diagnostic workflow optimization.

Bethyl will also work with Biocare to develop novel solutions in automated immunohistochemistry workflows to expand platform options available to pharmaceutical and biotechnology research institutions.

Caris brings precision medicine assays closer to market
Caris Life Sciences has submitted premarket approval applications to the U.S. Food and Drug Administration for its MI Exome CDx and MI Transcriptome CDx...